Scarica l'app Stockscreener
111.90
2.37%
-2.72
Dopo l'orario di chiusura:
111.95
0.05
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Merck Co Inc Borsa (MRK) Ultime notizie
Vanguard Group Inc. Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Acquired by Supplemental Annuity Collective Trust of NJ - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Sanctuary Advisors LLC - MarketBeat
Impax Asset Management Group plc Decreases Stock Position in Merck & Co., Inc. $MRK - MarketBeat
M&T Bank Corp Sells 1,452,939 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stake Increased by AEGON ASSET MANAGEMENT UK Plc - MarketBeat
Merck and the Healthcare Sector Rotation Analysis - HarianBasis.co
Merck & Co., Inc. $MRK is Munich Reinsurance Co Stock Corp in Munich's 4th Largest Position - MarketBeat
J.P. Marvel Investment Advisors LLC Has $3.02 Million Holdings in Merck & Co., Inc. $MRK - MarketBeat
Concurrent Investment Advisors LLC Grows Position in Merck & Co., Inc. $MRK - MarketBeat
Generali Investments Management Co LLC Raises Stock Position in Merck & Co., Inc. $MRK - MarketBeat
China Universal Asset Management Co. Ltd. Sells 19,894 Shares of Merck & Co., Inc. $MRK - MarketBeat
Jim Cramer Says “Merck Is Terrific” - Yahoo Finance
MRK Stock Quote Price and Forecast - CNN
Is Merck & Co. (MRK) One of the Best Bear Market Stocks to Invest in Right Now? - Insider Monkey
Infinimmune and Merck (MRK) Enter into an Antibody Discovery Agreement - Insider Monkey
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, - PharmiWeb.com
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc. - BioSpace
Mental Health Clinical Trials Research Report 2026: $4.89 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
Merck & Co., Inc. $MRK Shares Purchased by Cadinha & Co. LLC - MarketBeat
Arizona State Retirement System Sells 31,306 Shares of Merck & Co., Inc. $MRK - MarketBeat
MRK Stock Price, Quote & Chart | MERCK & CO. INC. (NYSE:MRK) - ChartMill
Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Merck & Co., Inc. $MRK Shares Sold by Teacher Retirement System of Texas - MarketBeat
United Asset Strategies Inc. Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (MRK) Gains FDA Priority Review for KEYTRUDA Regimen in Muscle-Invasive Bladder Cancer - Insider Monkey
Merck & Co., Inc. $MRK Shares Bought by Caprock Group LLC - MarketBeat
B. Metzler seel. Sohn & Co. AG Increases Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (MRK) to Release Earnings on Thursday - MarketBeat
Merck & Co. Inc. (MRK) Poised to Drive R&D and Operational Efficiency via New Google Cloud Agentic AI PartnershipUpside Surprise - Xã Thanh Hà
Merck & Co (MRK) Proxy filing Summary - Quartr
Merck to partner with Google Cloud on AI initiatives - Reuters
Merck & Co., Inc. $MRK Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
KLP Kapitalforvaltning AS Cuts Position in Merck & Co., Inc. $MRK - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Has $4.84 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
PFG Advisors Sells 11,759 Shares of Merck & Co., Inc. $MRK - MarketBeat
CPC Advisors LLC Increases Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Boston Trust Walden Corp - MarketBeat
Merck & Co., Inc. (MRK)Phase 3 Oncology Trial Setback Triggers Near-Term Pullback, Long-Term Upside Remains IntactNet Debt/EBITDA - Cổng thông tin điện tử tỉnh Tây Ninh
A Look at Merck & Co Inc (MRK) After 3.9% Decline -- GF Value $1 - GuruFocus
Merck And Eisai’s Keytruda/Lenvima/Welireg Trial In Kidney Cancer Fails - Citeline News & Insights
US FDA approves Merck's pill combo to treat HIV infection - Reuters
Merck's new once-daily HIV pill hits pharmacies after FDA nod - Stock Titan
FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) - Business Wire
Why Is Merck Stock Falling Tuesday? - Benzinga
FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC - BioWorld News
Merck & Co Inc Stock (MRK) Moved Down by 4.19% on Apr 21: A Full Analysis - TradingKey
Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock? - TradingView
Novem Group Purchases 9,205 Shares of Merck & Co., Inc. $MRK - MarketBeat
SageGuard Financial Group LLC Acquires Shares of 14,280 Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) - ACN Newswire
Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda - GlobeNewswire
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock new upside? - AD HOC NEWS
Duncker Streett & Co. Inc. Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - GlobeNewswire Inc.
Lobbying Update: $4,150,000 of MERCK & CO INC lobbying was just disclosed - Quiver Quantitative
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock sustained up - AD HOC NEWS
Merck & Co. Inc. stock underperforms Monday when compared to competitors - MarketWatch
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to sustain growth? - AD HOC NEWS
Merck & Co., Inc. Sued for Securities Law ViolationsInvestors - The National Law Review
Merck & Co., Inc. $MRK Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank - MarketBeat
TD Waterhouse Canada Inc. Grows Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough for sustained growth? - AD HOC NEWS
1.36%
6.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):